Global Gene Therapy Industry – GlobeNewswire

November 19, 2020 05:27 ET | Source: ReportLinker

New York, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gene Therapy Industry" - https://www.reportlinker.com/p05817594/?utm_source=GNW 6% in the year 2020 and thereafter recover and grow to reach US$3.3 billion by the year 2027, trailing a post COVID-19 CAGR of 19.5% over the analysis period 2020 through 2027. Governments worldwide are focusing all healthcare resources on fighting the global pandemic. Billions of dollars have poured into researching COVID-19 drugs, therapies and vaccines. Over US$8 billion globally excluding the U.S. has been pledged only for vaccine development. The U.S. has independently pumped billions of dollars into COVID-19 research and response. The massive reallocation of funds and reprioritization of efforts has left a glaring gap in other sectors of healthcare. Gene therapy which holds promise for treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia & AIDS, is slumping due to lack of research funds & reduced footfall of patients seeking treatment. Given the complex and fragile manufacturing and delivery system along with funding models of the industry, COVID-19 has emerged as a black swan event. Various players still find it challenging to ensure timely delivery of gene therapy to patients and clinical sites. There are concerns regarding administration of cell and gene therapies. The chances of virus transmission, mainly to people in the high-risk group, coerced hospitals to delay or cancel appointments. In addition, travel restrictions and stay-at-home orders discouraged patients from visiting to treatment centres. Treatments intended to be delivered into ICUs are being impacted by bed reservations made for patients with COVID-19 infection.

R&D and preclinical activities are also affected by supply shortages as a result of strong demand for consumables like reagents and PPE from COVID-19 laboratories. The clinical development segment suffered the most due to concerns regarding recruitment of patients and suspension of trial enrolments for protecting participants from the risk of infection. These issues are delaying activation of new sites, prompting players to postpone new clinical trials. However, the intensity of disruptions for cell and gene therapy trials was less in comparison to the pharmaceutical industry due to association of the former with rare and serious medical conditions, enabling participants to continue trials. While companies targeting paediatric diseases suspended trials, others dealing with oncology maintained the pace. COVID-19 has also impacted patient assessment and has made it difficult for companies to perform follow-up evaluations for trial participants. These issues are attributed to confluence of various factors like travel ban, withdrawal of several services from healthcare sites and the risk of virus transmission. In addition, these disruptions are anticipated to threaten existence of certain cell and gene therapy companies, particularly small-scale biotech players that are in pre-commercial phase and rely on external funding. As governments, stakeholders, pharmaceutical companies and venture capitalists invest in these players on the basis of research milestones, pipeline progress and data readouts, ability of these companies to secure future funding will also be affected.

In the post COVID-19 period, growth will be led by therapy indications in the field of oncology. Gene therapies hold promise to improve the condition of patients where traditional cancer treatments such as radiation and chemotherapy are not effective. Blood and lymphatic cancers hold huge potential as gene therapies can manipulate the genetic information to target the cancerous proteins, thereby enabling the body to fight against the cancers. Oncology will remain the key area of focus for gene therapy applications. Cancer therapies represent the leading category, as is gauged through robust rise in the number of molecules being tested across numerous clinical trials. Novartis which recently bagged the U.S. FDA approval for Kymriah, a gene therapy designed for the treatment of hematological cancer, is seeking to gain commercial approval in established and emerging countries. Similarly, Kite Pharma, the developer of YESCARTA, the first CAR T-cell therapy approved for certain types of non-Hodgkin lymphoma in adults, has formed a separate team to provide end-to-end support for its Yescarta customers including hospitals and clinics. Such efforts by developers would augment the use case of gene therapies in treatment of large B-cell lymphoma and acute lymphoblastic leukemia (ALL), the high potential cancer treatment verticals. More developmental focus will also be shed on monogenic rare diseases which have clearer genomic targets and the unmet need in smaller patient populations. Majority gene therapies so far have come to market through accelerated review pathways of regulatory authorities. In the year 2018 alone, over 150 applications for investigational new drugs for gene therapies were filed. In the coming years, there will be significant improvement in the number of approvals for new gene therapies. The growth is anticipated to emerge from different modalities including RNAi, ASOs and CRISPR gene editing based therapeutics which offer long term opportunities for growth. These technologies are generating much excitement for investors.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05817594/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1 A Prelude to Gene Therapy II-1 Classification of Gene Therapies II-1 Impact of Covid-19 and a Looming Global Recession II-2 COVID-19 Causes Gene Therapy Market to Buckle & Collapse II-2 COVID-19 Impact on Different Aspects of Gene Therapy II-2 Manufacturing & Delivery II-2 Research & Clinical Development II-3 Commercial Operations & Access II-3 Managing Derailed Operations II-4 Focus on Clinical Development Programs II-4 Targeting Manufacturing & Delivery Strategies II-4 Securing Supplies II-4 Remote Working II-4 Gene Therapy Set to Witness Rapid Growth Post COVID-19 II-5 By Vector Type II-5 VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET II-5 Adeno-Associated Virus Vectors II-6 Lentivirus II-6 NON-VIRAL VECTORS TO WITNESS FASTER GROWTH II-7 US and Europe Dominate the Gene Therapy Market II-8 Oncology Represents the Largest Indication for Gene Therapy II-9 Market Outlook II-9 WORLD BRANDS II-10

2. FOCUS ON SELECT PLAYERS II-16 Recent Market Activity II-18 Select Innovations II-24

3. MARKET TRENDS & DRIVERS II-25 Availability of Novel Therapies Drive Market Growth II-25 Select Approved Gene Therapy Products II-26 Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy II-27 Lentiviral Vectors Witness Increased Interest II-27 Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy II-28 Exhibit 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-28 Exhibit 2: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 II-29 Exhibit 3: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 II-30 Compelling Level of Technology & Innovation to Ignite Gene Therapy II-30 Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases II-31 Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine II-31 M&As Rampant in Gene Therapy Space II-31 Gene Therapy Deals: 2018 and 2019 II-32 Emphasis on Formulating Robust Regulatory Framework II-33 Strong Gene Therapy Pipeline II-33 Gene Therapy: Phase III Clinical Trials II-33 OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR II-35 Growing Funding for Gene Therapy Research II-35 Market Issues & Challenges II-35

4. GLOBAL MARKET PERSPECTIVE II-37 Table 1: World Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-37

Table 2: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-38

Table 3: World 10-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2020 & 2027 II-39

Table 4: World Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-40

Table 5: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-41

Table 6: World 10-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-42

Table 7: World Current & Future Analysis for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-43

Table 8: World Historic Review for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-44

Table 9: World 10-Year Perspective for Non-Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-45

Table 10: World Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-46

Table 11: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-47

Table 12: World 10-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-48

Table 13: World Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-49

Table 14: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-50

Table 15: World 10-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-51

Table 16: World Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-52

Table 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-53

Table 18: World 10-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-54

Table 19: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-55

Table 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-56

Table 21: World 10-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-57

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1 Table 22: USA Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-1

Table 23: USA Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-2

Table 24: USA 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-3

Table 25: USA Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-4

Table 26: USA Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-5

Table 27: USA 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-6

CANADA III-7 Table 28: Canada Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-7

Table 29: Canada Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-8

Table 30: Canada 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-9

Table 31: Canada Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-10

Table 32: Canada Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-11

Table 33: Canada 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-12

JAPAN III-13 Table 34: Japan Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-13

Table 35: Japan Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-14

Table 36: Japan 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-15

Table 37: Japan Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-16

Table 38: Japan Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-17

Table 39: Japan 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-18

CHINA III-19 Table 40: China Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-19

Table 41: China Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-20

Table 42: China 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-21

Table 43: China Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-22

Table 44: China Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-23

Table 45: China 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-24

EUROPE III-25 Table 46: Europe Current & Future Analysis for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 III-25

Table 47: Europe Historic Review for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-26

Table 48: Europe 10-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2020 & 2027 III-27

Table 49: Europe Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-28

Table 50: Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-29

Table 51: Europe 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-30

Table 52: Europe Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-31

Table 53: Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-32

Table 54: Europe 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-33

FRANCE III-34 Table 55: France Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-34

Table 56: France Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-35

Table 57: France 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-36

Table 58: France Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-37

Table 59: France Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-38

Table 60: France 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-39

GERMANY III-40 Table 61: Germany Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-40

Table 62: Germany Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-41

Table 63: Germany 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-42

Table 64: Germany Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-43

Table 65: Germany Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-44

Table 66: Germany 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-45

ITALY III-46 Table 67: Italy Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-46

Table 68: Italy Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-47

Table 69: Italy 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-48

Table 70: Italy Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-49

Table 71: Italy Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-50

Table 72: Italy 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-51

UNITED KINGDOM III-52 Table 73: UK Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-52

Table 74: UK Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-53

Table 75: UK 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-54

Table 76: UK Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-55

Table 77: UK Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-56

Table 78: UK 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-57

REST OF EUROPE III-58 Table 79: Rest of Europe Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-58

Table 80: Rest of Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-59

Table 81: Rest of Europe 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-60

Table 82: Rest of Europe Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-61

Table 83: Rest of Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-62

Table 84: Rest of Europe 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-63

ASIA-PACIFIC III-64 Table 85: Asia-Pacific Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-64

Table 86: Asia-Pacific Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-65

Table 87: Asia-Pacific 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-66

Read the original here:
Global Gene Therapy Industry - GlobeNewswire

Home Page of the Human Gene and Cell Therapy Center [Last Updated On: August 29th, 2015] [Originally Added On: August 29th, 2015]
Gene Therapy: Chinese Researching Gene Replacement [Last Updated On: September 25th, 2015] [Originally Added On: September 25th, 2015]
Medi-Cal: Medi-Cal Update - Clinics and Hospitals | May ... [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
Gene Therapy Market - Size, Share, industry, Forecast ... [Last Updated On: November 30th, 2016] [Originally Added On: November 30th, 2016]
Digital Journal: A Global Digital Media Network - Digital Journal (press release) [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
Cure for ageing could lie in gene therapy | WIRED UK [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
Advanced Gene-Targeted Therapies - Alternative Cancer Clinics [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
Alternative Cancer Clinics - Immunotherapy for Cancer [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
Stem cell therapies breaking barriers - Guardian (blog) [Last Updated On: July 9th, 2017] [Originally Added On: July 9th, 2017]
Cancer Biological Therapy market is rising with potential rate at CAGR of 4.7 % till 2023 - MENAFN.COM [Last Updated On: July 11th, 2017] [Originally Added On: July 11th, 2017]
Head and Neck Cancer Therapeutics Market is Expected to Generate Huge Profits by 2024 - MilTech [Last Updated On: July 12th, 2017] [Originally Added On: July 12th, 2017]
In a first, scientists edit fatal gene mutation out of DNA - Asheboro Courier Tribune [Last Updated On: August 4th, 2017] [Originally Added On: August 4th, 2017]
Proton Therapy: How It Could Change The Outcome of Paediatric Cancer - HuffPost [Last Updated On: August 5th, 2017] [Originally Added On: August 5th, 2017]
Wilson's Disease Market: Unmet Needs of Patient Population to Inspire Players for Improved Treatment Options - Edition Truth [Last Updated On: August 5th, 2017] [Originally Added On: August 5th, 2017]
Cardiovascular disease cure? One session of THIS could help treat condition - Express.co.uk [Last Updated On: August 9th, 2017] [Originally Added On: August 9th, 2017]
Understanding the muscle behind global duchenne muscular dystrophy market - WhaTech [Last Updated On: August 9th, 2017] [Originally Added On: August 9th, 2017]
Biological bypass shows promise in coronary artery disease - Medical Xpress [Last Updated On: August 12th, 2017] [Originally Added On: August 12th, 2017]
Sodium Iodide Symporter for Nuclear Molecular Imaging and ... [Last Updated On: August 13th, 2017] [Originally Added On: August 13th, 2017]
Traditional Therapy Clinics Ltd (TTC.AX) Money Flow Index Levels in Focus - Stock Daily Review [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
Gene Editing in Human Embryos Leaps ForwardHere's the Science - Singularity Hub [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
Global Cancer Biological Therapy Market 2017 Size, Development Status, Type and Application, Segmentation ... - Digital Journal [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
Orphan Diseases Market Key Players analysis ... - Digital Journal - Digital Journal [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
New Stanford drug saves child with deadly genetic disease - The Mercury News [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
Australian Market Declines - Markets Insider [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
How one California county is fighting high-priced surgeries - Los Angeles Times [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
New 'hit-and-run' gene editing tool temporarily rewrites genetics to treat cancer and HIV - GeekWire [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
Global Cancer Biological Therapy Analysis & Forecast 2016 to 2023 - Digital Journal [Last Updated On: September 5th, 2017] [Originally Added On: September 5th, 2017]
FDA Approves New Cancer Treatment - Alive For Football [Last Updated On: September 5th, 2017] [Originally Added On: September 5th, 2017]
FDA approves first cell-based gene therapy for use in the United States - Gears Of Biz [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
Quick Hits: Withdrawn Leukemia Drug Returning, Drugmaker in $58M Settlement Over Sales Reps, and More - MedShadow (registration) (blog) [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
Hacking Your Genes Has Never Been Easier - Outside Magazine [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
resurrection-clinics.eu [Last Updated On: August 24th, 2018] [Originally Added On: August 24th, 2018]
Cell and Gene Therapy Center - IQVIA [Last Updated On: December 24th, 2018] [Originally Added On: December 24th, 2018]
F.D.A. Speeds Review of Gene Therapies, Vowing to Target ... [Last Updated On: February 17th, 2019] [Originally Added On: February 17th, 2019]
Nutrition : The Addiction Recovery Guide [Last Updated On: March 25th, 2019] [Originally Added On: March 25th, 2019]
Gene Therapy: The New Frontier for Inherited Retinal Disease [Last Updated On: April 16th, 2019] [Originally Added On: April 16th, 2019]
4 Barriers To Cell And Gene Therapy Development For Rare ... [Last Updated On: May 18th, 2019] [Originally Added On: May 18th, 2019]
Google Bans Advertising on Unproven Medical Treatments (like Stem Cells) - Bedford Bulletin [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Biological Product Manufacturing Market Analysis, Size, Regional Outlook, Share, Trend, Growth, Analysis and Forecast - Rapid News Network [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Precision Cancer Therapies Market to Witness Comprehensive Growth by 2017 2025 - Technology Trend [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Targeted Cancer Therapies Market Regional Landscape, Production, Sales & Consumption Status and Prospects 2025 - Commerce Gazette [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Chemotherapy Drugs Market Strategies, Major Industry Participants, Marketing Channels and Forecast To2018 2028 - Commerce Gazette [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Texas State To Expand Round Rock Campus Programs, Services - Round Rock, TX Patch [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Transfusion-dependent Anemia Treatment Market Size, Status and Growth Opportunities by 2025 - The Market Plan [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Google bans ads for 'bad actors' selling 'deceptive treatments' - BioEdge [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
Precision Cancer Therapies Market Forecast Research Reports Offers Key Insights 2017 2025 - Space Market Research [Last Updated On: September 28th, 2019] [Originally Added On: September 28th, 2019]
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations - Renal and Urology News [Last Updated On: September 28th, 2019] [Originally Added On: September 28th, 2019]
Nearly Half of Poland's SMA Patients on Track to Get Spinraza, Experts Say - SMA News Today [Last Updated On: September 28th, 2019] [Originally Added On: September 28th, 2019]
Pollard and Norris in the race for Pos. 2 of the Public Hospital District 4 - Snoqualmie Valley Record [Last Updated On: September 28th, 2019] [Originally Added On: September 28th, 2019]
Social Impact Heroes: How Lynn OConnor Vos and the Muscular Dystrophy Association are helping to raise billions of dollars to fund research to... [Last Updated On: September 28th, 2019] [Originally Added On: September 28th, 2019]
Non-viral Gene Therapy will now accelerate cancer study - Industry Reporter [Last Updated On: September 28th, 2019] [Originally Added On: September 28th, 2019]
Transfusion-dependent Anemia Treatment Market Gain Impetus due to the Growing Demand over 2019 2029 - Herald Space [Last Updated On: October 1st, 2019] [Originally Added On: October 1st, 2019]
Parkinsons Disease Treatment Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025 - The Ukiah Post [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
The Patient Perspective On Patient Centricity Insights From A Veteran Of 5 Clinical Trials - Clinical Leader [Last Updated On: October 12th, 2019] [Originally Added On: October 12th, 2019]
Deepak Chopra Has Never Been Sick - The New Yorker [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today [Last Updated On: October 31st, 2019] [Originally Added On: October 31st, 2019]
Davenport & Company Upped By $3.56 Million Its Sgmo (SGMO) Holding; EMPOWER CLINICS ORDINARY SHARES (EPWCF) Shorts Raised By 2360% - MS Wkly [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) - The Market Expedition [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell... [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment - The Market Journal [Last Updated On: November 11th, 2019] [Originally Added On: November 11th, 2019]
Abuse in cell banking services a global problem - Bioprocess Insider - BioProcess Insider [Last Updated On: November 14th, 2019] [Originally Added On: November 14th, 2019]
Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia... [Last Updated On: November 18th, 2019] [Originally Added On: November 18th, 2019]
U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa - Ottawa Citizen [Last Updated On: November 18th, 2019] [Originally Added On: November 18th, 2019]
Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT - Yahoo Finance [Last Updated On: November 20th, 2019] [Originally Added On: November 20th, 2019]
Macular Degeneration Treatment Market and its Future Outlook and Trend During the Period of 2019 2026 - The Chicago Sentinel [Last Updated On: November 25th, 2019] [Originally Added On: November 25th, 2019]
Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference - Thehour.com [Last Updated On: November 28th, 2019] [Originally Added On: November 28th, 2019]
Global Parkinsons Disease Treatment Market 2019 Analysis by Industry Growth, Size, Share, Trends and Forecast by 2025 - Eastlake Times [Last Updated On: November 30th, 2019] [Originally Added On: November 30th, 2019]
World AIDS Day 2019: 37.9M people worldwide were living with HIV at the end of 2018 - USA TODAY [Last Updated On: December 2nd, 2019] [Originally Added On: December 2nd, 2019]
Precision Cancer Therapies Market Size, Status and Forecast 2025 Trends, Size, Drivers, Strategies, Products and - The Market Stats News [Last Updated On: December 6th, 2019] [Originally Added On: December 6th, 2019]
Counterculture 73: Summer Jam, Timothy Leary and the Sexual Revolution - Rolling Stone [Last Updated On: December 6th, 2019] [Originally Added On: December 6th, 2019]
Cancer gene therapy backed by Blackstone gets trial win - BioPharma Dive [Last Updated On: December 6th, 2019] [Originally Added On: December 6th, 2019]
Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Tribunal... [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
Mergers and Acquisitions Will Strengthen Payer Identity in 2020 - HealthPayerIntelligence.com [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
University of Iowa researchers say $18 million grant could soon lead to cure for rare brain disease - KCRG [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
ICMR issues guidelines for gene therapy in India - Daily Pioneer [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
US Network of Specialized Angelman Clinics to Double Thanks to New Partnership - Angelman Syndrome News [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
This was the best health news over the last decade - USA TODAY [Last Updated On: December 18th, 2019] [Originally Added On: December 18th, 2019]
Top Providers of the Alpha Thalassemia Market gives a New Dimension easing Measurement and Quantification - GuruFocus.com [Last Updated On: December 27th, 2019] [Originally Added On: December 27th, 2019]
Novel discovery in gene therapy to treat kidney diseases - WeForNews [Last Updated On: January 5th, 2020] [Originally Added On: January 5th, 2020]
Insights on precision oncology developments in Japan and beyond - MobiHealthNews [Last Updated On: January 6th, 2020] [Originally Added On: January 6th, 2020]

Stem Cell Clinic

Stem Cell News

Global Gene Therapy Industry – GlobeNewswire